Targeting truncated RXRα for cancer therapy

Retinoid X receptor-alpha (RXRα), a unique member of the Nuclear Receptor Superfamily, is a well-established drug target, representing one of the most important targets for pharmacologic interventions and therapeutic applications for Cancer. However, how RXRα regulates Cancer cell growth and how RXRα modulators suppress tumorigenesis are poorly understood. Altered expression and aberrant function of RXRα are implicated in the development of Cancer. Previously, several studies had demonstrated the presence of N-terminally truncated RXRα (tRXRα) proteins resulted from limited proteolysis of RXRα in tumor cells. Recently, we discovered that overexpression of tRXRα can promote tumor growth by interacting with tumor necrosis factor-alpha-induced phosphoinositide 3-kinase and NF-κB signal transduction pathways. We also identified nonsteroidal anti-inflammatory drug Sulindac and analogs as effective inhibitors of tRXRα activities via a unique binding mechanism. This review discusses the emerging roles of tRXRα and modulators in the regulation of Cancer cell survival and death as well as inflammation and our recent understanding of tRXRα regulation by targeting the alternate binding sites on its surface.

PI3K; RXRα modulators; inflammation; nongenomic action; tRXRα.